John F' Manzello President

1

Promosome Corporate Introduction

• John F. ManzelloPresident CEO
• 369 Lexington Avenue, 17th Floor
• New York, NY 10017
• jmanzello_at_promosome.com
• [phone]

2

Promosome LLC

• Promosome is a New York City based
  biotechnology company .
• Founded in 2003 (Series A) to commercialize the
  discoveries of Nobel Laureate Dr. Gerald M.
  Edelman, his colleague Dr. Vincent Mauro and
  other researchers at The Scripps Research
  Institute in La Jolla, CA.
• The expertise and continued focus of this
  research team at Scripps is in areas of Gene
  Regulation and Protein Expression through
  Translation Initiation.
• Through this expertise the Scripps team has
  developed a world leading understanding of the
  fundamental aspects of mRNA translation as well
  as several commercially capable technologies.

3

Promosome LLC The Scripps Research
Institute

• The Scripps Partnership
• 2 Year Research Funding and Option (RFO)
  Agreement in place establishing a relationship
  with Promosome and the laboratories of Drs.
  Edelman and Mauro.
• Through the RFO, Promosome has exclusive, sole,
  worldwide rights to license any and all
  translational discoveries related to
  bioproduction and DNA vaccine.
• Scripps 12 founders interest, subject to
  normal dilution no future royalties.

4

Promosome LLC,

• This Scripps based knowledge is already being
  leveraged to drive a number of significant
  biotechnology solutions relating to enhanced
  protein expression within bioproduction.
• Additionally, The Scripps knowledge is
  anticipated to drive future enablement in DNA
  Vaccines and Large Molecule Therapeutics.
• These applications mirror Promosomes business
  model, the
• anticipated growth and organizational evolution
  is established as
• Increased Protein Expression through TEEs
  Landing Pad (Commercial Stage)
• DNA Vaccine Enablement Platform ( Research
  Stage)
• 2ND Generation of Expression Enabling
  Technologies (Research Stage)
• Protein Therapeutics (Future Stage)

5

Technology License / Patent History

• Positive Feedback Selection Technology
  (Discovery of TEEs )
• - Patent Application - April 2007
• - License to Promosome - April 2007
• Translational Enhancer Elements (TEEs for
  Increased Protein Expression through
  Translation Initiation)
• - Patent Application - December 2007
• - License to Promosome January 2008
• Landing Pad (Rapid Creation of Stable High
  Expressing Cell Lines)
• - Late Stage RD
• - Anticipated Application in Q3 2009
• TEEs in Human Dendritic Cells for DNA
  Vaccine Enablement
• - Early Stage RD

6

Finances

• In October of 2008, Promosome closed on its
  Series B Financial Round securing 9.6 Million
  (USD) of funding through various institutional
  and non-institutional participation. This
  financing has provided ample runway for
  corporate operations, the commercialization of
  TSRI based technologies as well as the
  maintenance of the TSRI Research Funding and
  Option Agreement.